Last reviewed · How we verify
DPI-386 Nasal Gel — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
DPI-386 Nasal Gel (DPI-386 Nasal Gel) — Repurposed Therapeutics, Inc.. DPI-386 is a repurposed therapeutic delivered as a nasal gel formulation, designed to provide local or systemic therapeutic effects through intranasal administration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DPI-386 Nasal Gel TARGET | DPI-386 Nasal Gel | Repurposed Therapeutics, Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DPI-386 Nasal Gel CI watch — RSS
- DPI-386 Nasal Gel CI watch — Atom
- DPI-386 Nasal Gel CI watch — JSON
- DPI-386 Nasal Gel alone — RSS
Cite this brief
Drug Landscape (2026). DPI-386 Nasal Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/dpi-386-nasal-gel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab